PATIENTS WITH BRCA MUTATIONS HAVE SUPERIOR OUTCOMES AFTER INTRAPERITONEAL CHEMOTHERAPY (IP) IN OPTIMALLY RESECTED HIGH GRADE OVARIAN CANCER (HGOC)

被引：0
|
作者：
Naumann, R. W. [1 ]
Symanowski, J. T. [2 ]
Morris, J. [1 ]
Crane, E. [1 ]
Tait, D. [1 ]
Higgins, R. V. [1 ]
Drury, L. [1 ]
North, L. [1 ]
Brown, J. [1 ]
机构：
[1] Carolinas Med Ctr, Levine Canc Inst, Ob Gyn, Charlotte, NC 28203 USA
[2] Carolinas Med Ctr, Levine Canc Inst, Biostat, Charlotte, NC 28203 USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2018年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCS8-1393
引用
收藏
页码：789 / 790
页数：2
相关论文
共 50 条
  • [31] Comparison of outcomes in optimally-cytoreduced ovarian cancer patients receiving postoperative intraperitoneal chemotherapy vs intravenous dose-dense chemotherapy without bevacizumab
    Schlappe, B.
    O'Cearbhaill, R.
    Zhou, Q.
    Iasonos, A.
    Mueller, J. J.
    Zivanovic, O.
    Gardner, G. J.
    Roche, K. Long
    Sonoda, Y.
    Chi, D. S.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 136 - 136
  • [32] Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study
    Ballesta-Lopez, Octavio
    Albert-Mari, Asuncion
    Borrell-Garcia, Carmela
    Melian-Sosa, Marcos
    Salvador-Coloma, Carmen
    Santaballa-Bertran, Ana
    Poveda-Andres, Jose Luis
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (02) : 268 - 278
  • [33] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for recurrent high grade serous ovarian cancer
    Lee, Jimin
    Kim, Jeeyeon
    Son, Joo-Hyuk
    Kong, Tae-Wook
    Chang, Suk-Joon
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A190 - A190
  • [34] Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer
    Meghal, Trishala
    Dave, Vishangi
    Tang, Horace
    Kumar, Vivek
    Xu, Yiqing
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2019, 10 (05): : 201 - 212
  • [35] Adjuvant chemotherapy for high-grade appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
    Baron, Ekaterina
    Sardi, Armando
    King, Mary Caitlin
    Nikiforchin, Andrei
    -Ramirez, Felipe Lopez
    Nieroda, Carol
    Gushchin, Vadim
    Ledakis, Panayotis
    EJSO, 2023, 49 (01): : 179 - 187
  • [36] Effects of neoadjuvant hyperthermic intraperitoneal chemotherapy on chemotherapy response score and recurrence for high-grade serous ovarian cancer patients with advanced disease
    Li, J.
    Wu, M-F.
    Li, H.
    Lin, Z-Q.
    Wang, L-J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1336 - S1336
  • [37] Morbidity and Mortality Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer
    Kim, Migang
    Lee, Yong Jae
    Seon, Ki Eun
    Kim, Sunghoon
    Lee, Chan
    Park, Hyun
    Choi, Min Chul
    Lee, Jung-Yun
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (05)
  • [38] Clinical outcomes of postoperative intraperitoneal chemotherapy for patients with early-stage high-grade serous ovarian cancer (HGSC) treated at British Columbia cancer agency.
    Lee, Joohyun
    Tinker, Anna
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
    Claudia Marchetti
    Marco D’Indinosante
    Carolina Bottoni
    Chiara Di Ilio
    Stefano Di Berardino
    Barbara Costantini
    Angelo Minucci
    Laura Vertechy
    Giovanni Scambia
    Anna Fagotti
    Scientific Reports, 11
  • [40] NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
    Marchetti, Claudia
    D'Indinosante, Marco
    Bottoni, Carolina
    Di Ilio, Chiara
    Di Berardino, Stefano
    Costantini, Barbara
    Minucci, Angelo
    Vertechy, Laura
    Scambia, Giovanni
    Fagotti, Anna
    SCIENTIFIC REPORTS, 2021, 11 (01)
12345